Nothing Special   »   [go: up one dir, main page]

AR019896A1 - Agente con efecto antidepresivo - Google Patents

Agente con efecto antidepresivo

Info

Publication number
AR019896A1
AR019896A1 ARP990103294A ARP990103294A AR019896A1 AR 019896 A1 AR019896 A1 AR 019896A1 AR P990103294 A ARP990103294 A AR P990103294A AR P990103294 A ARP990103294 A AR P990103294A AR 019896 A1 AR019896 A1 AR 019896A1
Authority
AR
Argentina
Prior art keywords
agent
antidepressive effect
antidepressive
effect
pramipexole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP990103294A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR019896A1 publication Critical patent/AR019896A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente concierne a la utilizacion de 2-amino-4,5,6,7-tetrahidro-6-propilamino-benzotiazol (pramipexol), de su enantiomero (-) o de una de sus salesfarmacologicamente compatibles, en combinacion con sertralina, para el tratamiento mejorado dedep resiones y estados depresivos.
ARP990103294A 1998-07-07 1999-07-07 Agente con efecto antidepresivo Suspension/Interruption AR019896A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (1)

Publication Number Publication Date
AR019896A1 true AR019896A1 (es) 2002-03-20

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103294A Suspension/Interruption AR019896A1 (es) 1998-07-07 1999-07-07 Agente con efecto antidepresivo

Country Status (33)

Country Link
US (1) US6255329B1 (es)
EP (1) EP1093369B1 (es)
JP (1) JP2002520273A (es)
KR (1) KR100557692B1 (es)
CN (1) CN1230168C (es)
AR (1) AR019896A1 (es)
AT (1) ATE228365T1 (es)
AU (1) AU762128B2 (es)
BG (1) BG64972B1 (es)
BR (1) BR9911768A (es)
CA (1) CA2336833C (es)
CZ (1) CZ294087B6 (es)
DE (2) DE19830201A1 (es)
DK (1) DK1093369T3 (es)
EA (1) EA003142B1 (es)
EE (1) EE04296B1 (es)
ES (1) ES2183583T3 (es)
HK (1) HK1037976A1 (es)
HU (1) HUP0103922A3 (es)
ID (1) ID27776A (es)
IL (1) IL140603A0 (es)
MY (1) MY117969A (es)
NO (1) NO20010064L (es)
NZ (1) NZ509729A (es)
PL (1) PL195043B1 (es)
PT (1) PT1093369E (es)
RS (1) RS49795B (es)
SK (1) SK284923B6 (es)
TR (1) TR200100146T2 (es)
TW (1) TW592698B (es)
WO (1) WO2000002542A2 (es)
YU (1) YU401A (es)
ZA (1) ZA200100090B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
AU2007253899A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) pramipexole and methods of using the same
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
WO2010022140A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
ES2459322T3 (es) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
CA2760527A1 (en) * 2009-04-30 2010-11-04 Supernus Pharmaceuticals, Inc. Method of treatment of depression
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
JP6329717B2 (ja) 2013-07-12 2018-05-23 ノップ バイオサイエンシーズ エルエルシー 高好酸球値および／または高好塩基球値の治療
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
CN110730662A (zh) 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法
MX2019015150A (es) 2017-06-30 2020-08-13 Chase Therapeutics Corp Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
EP0186087B1 (de) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
US6462048B2 (en) * 1996-03-29 2002-10-08 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
ES2231902T3 (es) * 1996-12-02 2005-05-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor de nk-1 para el tratamiento de transtornos del movimiento.
CN1293573A (zh) * 1998-01-13 2001-05-02 同步神经元有限责任公司 迟发性运动障碍和其它运动疾病的治疗方法

Also Published As

Publication number Publication date
NO20010064D0 (no) 2001-01-05
CZ294087B6 (cs) 2004-10-13
SK112001A3 (en) 2001-10-08
MY117969A (en) 2004-08-30
EE04296B1 (et) 2004-06-15
US6255329B1 (en) 2001-07-03
BG105112A (en) 2001-10-31
YU401A (sh) 2003-10-31
PT1093369E (pt) 2003-03-31
KR20010079491A (ko) 2001-08-22
TR200100146T2 (tr) 2001-07-23
EA200100084A1 (ru) 2001-08-27
ES2183583T3 (es) 2003-03-16
JP2002520273A (ja) 2002-07-09
NZ509729A (en) 2003-06-30
EP1093369A2 (de) 2001-04-25
TW592698B (en) 2004-06-21
WO2000002542A3 (de) 2000-06-22
BG64972B1 (bg) 2006-11-30
KR100557692B1 (ko) 2006-03-07
PL345842A1 (en) 2002-01-14
IL140603A0 (en) 2002-02-10
SK284923B6 (sk) 2006-02-02
ATE228365T1 (de) 2002-12-15
EP1093369B1 (de) 2002-11-27
WO2000002542A2 (de) 2000-01-20
PL195043B1 (pl) 2007-08-31
DE19830201A1 (de) 2000-01-13
DK1093369T3 (da) 2002-12-16
HUP0103922A3 (en) 2002-08-28
EE200100014A (et) 2002-06-17
ID27776A (id) 2001-04-26
RS49795B (sr) 2008-06-05
CZ200177A3 (en) 2001-06-13
EA003142B1 (ru) 2003-02-27
CN1230168C (zh) 2005-12-07
ZA200100090B (en) 2002-04-04
AU762128B2 (en) 2003-06-19
CA2336833A1 (en) 2000-01-20
DE59903556D1 (de) 2003-01-09
NO20010064L (no) 2001-03-02
HUP0103922A2 (hu) 2002-03-28
CA2336833C (en) 2008-09-23
BR9911768A (pt) 2001-04-03
HK1037976A1 (en) 2002-03-01
AU5030399A (en) 2000-02-01
CN1308533A (zh) 2001-08-15

Similar Documents

Publication Publication Date Title
AR019896A1 (es) Agente con efecto antidepresivo
BR0013826A (pt) Formas orais de apresentação
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
AR033796A1 (es) Composicion farmaceutica
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
BR0212250A (pt) produto de cuidado pessoal, método de inibição de crescimento de mofos no mesmo
CA2301899A1 (en) Agent with an antidepressant activity
MX344589B (es) Instrumento para el cuidado oral que incluye un agente para el cuidado oral.
IL139164A (en) Riluzole and levodopa combinations for treating parkinson's disease
BRPI0407964A (pt) material para mancal plano perfurável
PT1044064E (pt) Dispositivo para o revestimento de granulos destinados a serem absorvidos por via oral
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK1560575T3 (da) 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf
ES2065307T3 (es) Producto y procedimiento para el moldeado permanente del cabello.
BR9811643A (pt) Suplementação quìmica de osso
BR0314804A (pt) Forma de dosagem de liberação modificada
BR0210632A (pt) Tratamento de doença parasìtica
ES2195405T3 (es) Derivado de tiadiazol carboxamida, agente fitosanitario, y utilizacion.
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
AR027958A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades vasculares, que comprende propionil l-carnitina y coenzima q10
FI20030379A0 (fi) Uusi farmaseuttinen koostumus
AR035273A1 (es) Pramipexol para el tratamiento del adhd
BR0316369B1 (pt) vestimenta para proteção parcial do corpo contra agentes biológicos.
ES1047265Y (es) Maquina perfeccionada para el ribeteado de calzados y similares.

Legal Events

Date Code Title Description
FB Suspension of granting procedure